IN2014CN04067A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04067A IN2014CN04067A IN4067CHN2014A IN2014CN04067A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A IN 4067CHN2014 A IN4067CHN2014 A IN 4067CHN2014A IN 2014CN04067 A IN2014CN04067 A IN 2014CN04067A
- Authority
- IN
- India
- Prior art keywords
- cancer
- vegf
- met
- directed
- treatment
- Prior art date
Links
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940125436 dual inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557358P | 2011-11-08 | 2011-11-08 | |
| PCT/US2012/064116 WO2013070890A1 (en) | 2011-11-08 | 2012-11-08 | Dual inhibitor of met and vegf for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04067A true IN2014CN04067A (enrdf_load_stackoverflow) | 2015-10-23 |
Family
ID=47179011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4067CHN2014 IN2014CN04067A (enrdf_load_stackoverflow) | 2011-11-08 | 2012-11-08 |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
| AU2012214322B2 (en) | 2011-02-10 | 2017-04-27 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| WO2012151326A1 (en) | 2011-05-02 | 2012-11-08 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| CA2852771C (en) | 2011-10-20 | 2019-11-26 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| HK1207587A1 (en) | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| AU2014232714B2 (en) | 2013-03-15 | 2018-07-19 | Exelixis, Inc. | Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| MX2021001583A (es) | 2014-02-14 | 2023-02-08 | Exelixis Inc | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. |
| CN106255499A (zh) | 2014-03-17 | 2016-12-21 | 埃克塞里艾克西斯公司 | 卡博替尼制剂的给药 |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| UA121482C2 (uk) | 2014-08-05 | 2020-06-10 | Екселіксіс, Інк. | Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| KR102262280B1 (ko) * | 2016-10-18 | 2021-06-09 | 베이징 콘런스 파마슈티칼 컴퍼니 리미티드 | 퀴놀린기로 치환된 카르복실산 화합물 또는 그의 약학적으로 허용 가능한 염, 그의 약학적 조성물 및 용도 |
| US11279675B2 (en) | 2017-05-26 | 2022-03-22 | Exelixis, Inc. | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
| LT3743070T (lt) | 2018-01-26 | 2025-11-10 | Junginiai, skirti nuo kinazės priklausomų sutrikimų gydymui | |
| TWI836629B (zh) | 2018-06-15 | 2024-03-21 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| AU2011307309A1 (en) * | 2010-09-27 | 2013-05-02 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| SI2621481T2 (sl) * | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
-
2012
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Ceased
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en not_active Ceased
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
- 2012-11-08 HK HK15102604.7A patent/HK1202062A1/xx unknown
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013070890A1 (en) | 2013-05-16 |
| EP2776033A1 (en) | 2014-09-17 |
| CA2854336A1 (en) | 2013-05-16 |
| CN104159585A (zh) | 2014-11-19 |
| TW201322981A (zh) | 2013-06-16 |
| KR20140088610A (ko) | 2014-07-10 |
| EA201490944A1 (ru) | 2014-10-30 |
| US20140323522A1 (en) | 2014-10-30 |
| TW201818937A (zh) | 2018-06-01 |
| BR112014011009A2 (pt) | 2017-06-06 |
| TWI662962B (zh) | 2019-06-21 |
| IL232421A0 (en) | 2014-06-30 |
| AU2017225103A1 (en) | 2017-09-28 |
| MX2014005458A (es) | 2015-04-16 |
| AU2012335737A1 (en) | 2014-06-05 |
| JP2018048154A (ja) | 2018-03-29 |
| HK1202062A1 (en) | 2015-09-18 |
| JP2014532766A (ja) | 2014-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04067A (enrdf_load_stackoverflow) | ||
| MX352926B (es) | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. | |
| HK1207587A1 (en) | A dual met - vegf modulator for treating osteolytic bone metastases | |
| IL224370B (en) | Combination treatment for prostate carcinoma | |
| IL304337A (en) | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases | |
| IL232530A0 (en) | Combined cancer treatment | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| BR112013024211A2 (pt) | tratamento de tumores sólidos | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| IL225689A0 (en) | Cancer treatment/inhibition of metastasis | |
| IL228430A0 (en) | Cancer treatment | |
| ZA201300762B (en) | Novel combination therapy for the treatment of cancer | |
| IN2014DN00254A (enrdf_load_stackoverflow) | ||
| MX2013006526A (es) | Dosis de los derivados de arilsulfonamida. | |
| HK1187831A (en) | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases | |
| HK1187832A (en) | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases | |
| GB201017316D0 (en) | Treatment of cancer/inhibition of metastasis | |
| GB201017356D0 (en) | Combination treatment of cancer | |
| GB201121791D0 (en) | Combination treatment of cancer | |
| GB201017354D0 (en) | Treatment of cancer | |
| JO3550B1 (ar) | مركب لمعالجة سرطان البروستاتا | |
| TH0901005197A (th) | การบำบัดต้านการเจริญเติบโตของเส้นโลหิตสำหรับการรักษาของโรคมะเร็งเต้านม | |
| GB201121783D0 (en) | Treatment of cancer |